{"id":"trissodium-citrate-30","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypocalcemia (if administered systemically)"},{"rate":null,"effect":"Citrate toxicity (metabolic alkalosis, hypernatremia)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Trisodium citrate binds ionized calcium (Ca2+) in blood, reducing the concentration of free calcium required for multiple steps of the coagulation cascade. By lowering available calcium, it prevents the activation of clotting factors and thrombin generation. This mechanism makes it useful as an anticoagulant in blood collection tubes and extracorporeal circuits.","oneSentence":"Trisodium citrate acts as an anticoagulant by chelating calcium ions, thereby inhibiting the coagulation cascade and preventing blood clot formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:14:12.175Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anticoagulant for blood collection and laboratory testing"},{"name":"Anticoagulant for extracorporeal circulation and dialysis"}]},"trialDetails":[{"nctId":"NCT02618317","phase":"PHASE4","title":"Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2013-07","conditions":"Chronic Kidney Disease","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CitraLock(Trade Mark)"],"phase":"marketed","status":"active","brandName":"Trissodium Citrate 30%","genericName":"Trissodium Citrate 30%","companyName":"University of Sao Paulo","companyId":"university-of-sao-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trissodium Citrate 30% is a small molecule used as a lock solution for long-term central venous catheters in patients with chronic kidney disease undergoing hemodialysis. It is one of three interventions being compared in a clinical trial for its effectiveness and safety in this context.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}